Cargando…
Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma
BACKGROUND: Outcomes of patients with metastatic melanoma discontinuing BRAF‐targeted therapy for cumulative toxicity after sustained response are unknown. MATERIALS AND METHODS: This retrospective case series analysis conducted at a single Cancer Center in Italy included patients with BRAF mutated...
Autores principales: | Di Guardo, Lorenza, Randon, Giovanni, Corti, Francesca, Vallacchi, Viviana, Raimondi, Alessandra, Fucà, Giovanni, Bini, Marta, Maurichi, Andrea, Patuzzo, Roberto, Gallino, Gianfrancesco, Mattavelli, Ilaria, Ruggeri, Roberta, Angi, Martina, Cossa, Mara, Valeri, Barbara, Cimminiello, Carolina, Santinami, Mario, Rivoltini, Licia, de Braud, Filippo, Rodolfo, Monica, Vecchio, Michele Del |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8649022/ https://www.ncbi.nlm.nih.gov/pubmed/34355463 http://dx.doi.org/10.1002/onco.13926 |
Ejemplares similares
-
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
por: Lacouture, Mario E., et al.
Publicado: (2016) -
Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020) -
Comprehensive Clinical Trial Data Summation for BRAF‐MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma
por: Luke, Jason J.
Publicado: (2019) -
Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021) -
Multidisciplinary Care of BRAF‐Mutant Stage III Melanoma: A Physicians Perspective Review
por: Cornelius, Lynn A., et al.
Publicado: (2021)